Thus, continued Orai1 expression may underlie the susceptible activation of Th17 cells, suggesting that Orai-mediated Ca2+ mechanisms may be an attractive therapeutic target against CKD progression or immune-mediated inflammatory renal fibrosis. Here, ORAI1 is linked to chronic kidney disease.